Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Volume 12, Number 3—March 2006

Research

Medication Sales and Syndromic Surveillance, France

Elisabeta Vergu*†‡1Comments to Author , Rebecca F. Grais*†1, Hélène Sarter*†, Jean-Paul Fagot*†, Bruno Lambert§, Alain-Jacques Valleron*†¶, and Antoine Flahault*†#
Author affiliations: *Institut National de la Santé et de la Recherche Medicale Unité, Paris, France; †Université Pierre et Marie Curie, Paris, France; ‡Institut National de la Recherche Agronomique MIA, Jouy-en-Josas, France; §IMS FRANCE, Puteaux, France; ¶Hôpital Saint-Antoine, Paris, France; #Hôpital Tenon, Paris, France

Main Article

Figure 1

Example of weekly consumption of expectorants and cephalosporins (provided by IMS France) in phase with weekly incidence of influenzalike illness (ILI) (data from French Sentinel Network) per 100,000 population.

Figure 1. Example of weekly consumption of expectorants and cephalosporins (provided by IMS France) in phase with weekly incidence of influenzalike illness (ILI) (data from French Sentinel Network) per 100,000 population.

Main Article

1Both authors contributed equally to this research.

Page created: January 27, 2012
Page updated: January 27, 2012
Page reviewed: January 27, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external